← FDA DRUG APPROVALS

FDA ANDA · ANDA074531

FLUPHENAZINE DECANOATE

Sponsor: HIKMA

APPLICATION
ANDA074531
TYPE
ANDA
ORIGINAL APPROVAL
1996-08-30
LATEST ACTION
2025-02-19
ROUTE
INTRAMUSCULAR, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

FLUPHENAZINE DECANOATEPrescription
FLUPHENAZINE DECANOATE 25MG/ML · INJECTABLE · INJECTION

Approval history

2025-02-19Labeling · Supplement 20 · standardAP
2017-02-23Labeling · Supplement 15 · standardAP
2013-10-17Labeling · Supplement 13 · standardAP
2010-12-03Labeling · Supplement 9AP
2009-05-22Labeling · Supplement 8AP
2008-10-30Labeling · Supplement 7AP
2008-08-19Labeling · Supplement 6AP
2001-04-03Manufacturing (CMC) · Supplement 1ReviewAP
1996-08-30OriginalOtherAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →